Background: Treatment of infections in the ICU represents a great challenge, especially infections caused by Gram-negative organisms. Rapid introduction of appropriate antimicrobial therapy is crucial to reduce mortality, and resistance rates in the ICU can be elevated due to antimicrobial selection pressure. Objectives: To evaluate the frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs. Methods: A total of 6091 bacterial isolates were consecutively collected from 75 US medical centres in 2015-17 as part of the International Network for Optimal Resistance Monitoring (INFORM) programme and tested for susceptibility to multiple antimicrobial agents at a central laboratory by reference broth microdilution methods. Results: The most common organisms were Staphylococcus aureus (30.0%), Pseudomonas aeruginosa (20.7%), Klebsiella spp. (11.8%), Enterobacter spp. (8.3%), Escherichia coli (7.1%) and Stenotrophomonas maltophilia (5.1%). Colistin (99.8% susceptible), ceftazidime/avibactam (96.8% susceptible in 2015-17 and 96.2% in 2017) and ceftolozane/tazobactam (96.5% susceptible in 2017) were the most active compounds against P. aeruginosa. Ceftazidime/avibactam (100.0% susceptible), amikacin (99.4% susceptible) and meropenem (97.6% susceptible) were the most active compounds against Enterobacteriaceae. S. maltophilia and Acinetobacter baumannii exhibited high resistance rates to most antimicrobials tested. Conclusions: Gram-negative bacteria were isolated from 67.1% of the patients and P. aeruginosa and Enterobacteriaceae represented >80% of these organisms. Ceftazidime/avibactam and amikacin provided the best coverage against Gram-negative organisms overall.
Background: Treatment of infections in the ICU represents a great challenge, especially infections caused by Gram-negative organisms. Rapid introduction of appropriate antimicrobial therapy is crucial to reduce mortality, and resistance rates in the ICU can be elevated due to antimicrobial selection pressure. Objectives: To evaluate the frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs. Methods: A total of 6091 bacterial isolates were consecutively collected from 75 US medical centres in 2015-17 as part of the International Network for Optimal Resistance Monitoring (INFORM) programme and tested for susceptibility to multiple antimicrobial agents at a central laboratory by reference broth microdilution methods. Results: The most common organisms were Staphylococcus aureus (30.0%), Pseudomonas aeruginosa (20.7%), Klebsiella spp. (11.8%), Enterobacter spp. (8.3%), Escherichia coli (7.1%) and Stenotrophomonas maltophilia (5.1%). Colistin (99.8% susceptible), ceftazidime/avibactam (96.8% susceptible in 2015-17 and 96.2% in 2017) and ceftolozane/tazobactam (96.5% susceptible in 2017) were the most active compounds against P. aeruginosa. Ceftazidime/avibactam (100.0% susceptible), amikacin (99.4% susceptible) and meropenem (97.6% susceptible) were the most active compounds against Enterobacteriaceae. S. maltophilia and Acinetobacter baumannii exhibited high resistance rates to most antimicrobials tested. Conclusions: Gram-negative bacteria were isolated from 67.1% of the patients and P. aeruginosa and Enterobacteriaceae represented >80% of these organisms. Ceftazidime/avibactam and amikacin provided the best coverage against Gram-negative organisms overall.
Authors: Robert K Flamm; Dee Shortridge; Mariana Castanheira; Helio S Sader; Michael A Pfaller Journal: Antimicrob Agents Chemother Date: 2019-10-22 Impact factor: 5.191
Authors: Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici Journal: Clin Microbiol Rev Date: 2020-11-11 Impact factor: 26.132
Authors: Ignacio Martin-Loeches; Jean-François Timsit; Marin H Kollef; Richard G Wunderink; Nobuaki Shime; Martin Nováček; Ülo Kivistik; Álvaro Réa-Neto; Christopher J Bruno; Jennifer A Huntington; Gina Lin; Erin H Jensen; Mary Motyl; Brian Yu; Davis Gates; Joan R Butterton; Elizabeth G Rhee Journal: J Antimicrob Chemother Date: 2022-03-31 Impact factor: 5.758
Authors: Maria F Mojica; Romney Humphries; John J Lipuma; Amy J Mathers; Gauri G Rao; Samuel A Shelburne; Derrick E Fouts; David Van Duin; Robert A Bonomo Journal: JAC Antimicrob Resist Date: 2022-05-05
Authors: Sibylle H Lob; Daryl D DePestel; C Andrew DeRyke; Krystyna M Kazmierczak; Katherine Young; Mary R Motyl; Daniel F Sahm Journal: Open Forum Infect Dis Date: 2021-06-16 Impact factor: 3.835